Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 83

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 8
Chunk 83
---
:North America(a)$1,779 $2,211 $3,610 $7,600 Western Europe1,861 1,164 1,222 4,247 Other developed markets(b)235 371 282 888 High-growth markets(c)1,385 1,503 2,107 4,995 Total$5,260 $5,249 $7,221 $17,730 Revenue type:Recurring$4,741 $3,566 $6,496 $14,803 Nonrecurring519 1,683 725 2,927 Total$5,260 $5,249 $7,221 $17,730 For the Nine-Month Period Ended September 27, 2024:Geographical region:North America(a)$1,624 $2,362 $3,536 $7,522 Western Europe1,700 1,111 1,154 3,965 Other developed markets(b)238 361 295 894 High-growth markets(c)1,328 1,463 2,165 4,956 Total$4,890 $5,297 $7,150 $17,337 Revenue type:Recurring$4,209 $3,628 $6,424 $14,261 Nonrecurring681 1,669 726 3,076 Total$4,890 $5,297 $7,150 $17,337 (a) The Company defines North America as the United States and Canada.(b) The Company defines other developed markets as all the markets of the world that are not North America, Western Europe or high-growth markets.(c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand).  The Company defines developed markets as all markets of the world that are not high-growth markets.The Company’s products and services primarily consist of life sciences research, biopharmaceutical drug production and medical diagnostic products and services.  The Company sells equipment to customers as well as consumables, software and services, some of which customers purchase on a recurring basis.